You are here

J Clin Oncol DOI:10.1200/JCO.20.00437

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.

Publication TypeJournal Article
Year of Publication2020
AuthorsBustoros, M, Sklavenitis-Pistofidis, R, Park, J, Redd, R, Zhitomirsky, B, Dunford, AJ, Salem, K, Tai, Y-T, Anand, S, Mouhieddine, TH, Chavda, SJ, Boehner, C, Elagina, L, Neuse, CJannes, Cha, J, Rahmat, M, Taylor-Weiner, A, Van Allen, E, Kumar, S, Kastritis, E, Leshchiner, I, Morgan, EA, Laubach, J, Casneuf, T, Richardson, P, Munshi, NC, Anderson, KC, Trippa, L, Aguet, F, Stewart, C, Dimopoulos, M-A, Yong, K, P Bergsagel, L, Manier, S, Getz, G, Ghobrial, IM
JournalJ Clin Oncol
PagesJCO2000437
Date Published2020 May 22
ISSN1527-7755
Abstract

PURPOSE: Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) with a 10% annual risk of progression. Various prognostic models exist for risk stratification; however, those are based on solely clinical metrics. The discovery of genomic alterations that underlie disease progression to MM could improve current risk models.

METHODS: We used next-generation sequencing to study 214 patients with SMM. We performed whole-exome sequencing on 166 tumors, including 5 with serial samples, and deep targeted sequencing on 48 tumors.

RESULTS: We observed that most of the genetic alterations necessary for progression have already been acquired by the diagnosis of SMM. Particularly, we found that alterations of the mitogen-activated protein kinase pathway ( and single nucleotide variants [SNVs]), the DNA repair pathway (deletion 17p, , and SNVs), and (translocations or copy number variations) were all independent risk factors of progression after accounting for clinical risk staging. We validated these findings in an external SMM cohort by showing that patients who have any of these three features have a higher risk of progressing to MM. Moreover, APOBEC associated mutations were enriched in patients who progressed and were associated with a shorter time to progression in our cohort.

CONCLUSION: SMM is a genetically mature entity whereby most driver genetic alterations have already occurred, which suggests the existence of a right-skewed model of genetic evolution from monoclonal gammopathy of undetermined significance to MM. We identified and externally validated genomic predictors of progression that could distinguish patients at high risk of progression to MM and, thus, improve on the precision of current clinical models.

DOI10.1200/JCO.20.00437
Pubmed

http://www.ncbi.nlm.nih.gov/pubmed/32442065?dopt=Abstract

Alternate JournalJ. Clin. Oncol.
PubMed ID32442065